Johns Hopkins Medicine Receives First Federal Grant for Psychedelic Treatment Research in 50 years

The question that remains to be answered: are psilocybin mushrooms -at the same dose of psilocybin - less, equal or more beneficial than pure psilocybin?

This is the first NIH grant awarded in over a half century to directly investigate the therapeutic effects of a classic psychedelic, consistent with a recent study published online that searched NIH funding and found zero grants were awarded between 2006 and 2020. Johns Hopkins Medicine will lead the multisite, three-year study in collaboration with University of Alabama at Birmingham and New York University. The study will be conducted simultaneously at the three institutions to diversify the pool of participants and increase confidence that results apply to a wide range of people who smoke. The grant, totaling nearly $4 million, is funded by NIH’s National Institute on Drug Abuse."⁣

Over the last 20 years, there has been a growing renaissance of research with classic psychedelics, which are the pharmacological class of compounds that includes psilocybin and LSD. These studies have been largely funded by philanthropy, resulting in impressive clinical findings for cancer-related existential distress, major depressive disorder and substance use disorders.

Can #psilocybin help smokers quit? #NIH National Institute on Drug Abuse has funded @HopkinsMedicine Matthew Johnson, Ph.D., to find out. @Drug_Researcher

https://www.hopkinsmedicine.org/news/newsroom/news-releases/johns-hopkins-medicine-receives-first-federal-grant-for-psychedelic-treatment-research-in-50-years via @HopkinsMedNews